Developer docs
API playgroundTry for free, no card

Search company profiles

Bio-Thera Solutions

Full company profile

uuid0004z1r

Namestring
Bio-Thera Solutions
Legal namestring
百奥泰生物制药股份有限公司
Websiteurl
bio-thera.com
Company typeenum
Public
Founded yearint
2003
Descriptiontext

Bio-Thera Solutions (百奥泰生物制药股份有限公司) is a Guangzhou-headquartered, publicly listed (Shanghai STAR Market, ticker 688177) commercial-stage biopharmaceutical company founded in 2003 that develops both biosimilars and innovative antibody drugs for oncology, autoimmune disease, cardiovascular disease, and ophthalmology. Its six proprietary technology platforms span antibody discovery (IDEAL engine, libraries of thousands of unique human antibody clones), AI-driven sequence-structure-function optimization, ADCC enhancement and Fc engineering, bispecific/multispecific dual-payload ADC construction with proprietary cleavable linkers, proprietary cell culture medium development, and full-chain quality research aligned with NMPA, FDA, and EMA standards. The company has 8 commercialized products: 格乐立®/Qletli® (adalimumab), 普贝希®/Avzivi®/Bevyx® (bevacizumab), 施瑞立®/TOFIDENCE® (tocilizumab), 贝塔宁® (bivalirudin, since transferred to Lepu in April 2026), 艾沙力®/喜沙立®/STARJEMZA®/Usymro® (ustekinumab), Gotenfia®/IMMGOLIS™ (golimumab), plus two BLAs under review (BAT4406F for NMOSD and BAT5906 for nAMD). The pipeline also includes multiple ADC candidates (BAT8006 FRα, BAT8008 Trop2, BAT8010 HER2, BAT8013 CD25), bispecific antibodies (BAT7111 PD-1/4-1BB, BAT7205 PD-L1/IL-15, BAT7104 PD-L1/CD47), and additional biosimilars (secukinumab, dupilumab, mepolizumab, pembrolizumab).

The business model is hybrid: Bio-Thera retains development, manufacturing, and supply of all products globally (66,500L current bioreactor capacity with 72,000L expansion planned at Yonghe, 91,744 m² facility), commercializes approved products directly in mainland China, and licenses regional commercialization rights to established pharmaceutical partners across the US (Accord BioPharma/Intas, Organon, Hikma), EU/UK/Switzerland (STADA, Gedeon Richter), MENA (Avalon, Jamjoom), Southeast Asia (Dr. Reddy's), Latin America (SteinCares), Canada (Accord), and India (Intas). Revenue mechanics include upfront fees, regulatory and development milestone payments, royalties on partner net sales (BAT2206 reaches 71+ countries), direct product sales in China, and one-time license transactions for mature assets (the CNY 450M Lepu deal being the most recent example). GMP certifications have been granted by NMPA, FDA, EMA, and ANVISA, supporting multi-region market access.

Short descriptiontext

Bio-Thera Solutions is a Guangzhou-based, publicly listed Chinese biopharmaceutical company developing biosimilars and innovative antibody drugs (including ADCs and bispecifics) for cancer, autoimmune, cardiovascular, and ophthalmic diseases, commercializing via global regional partners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersGuangzhou, China
HQ citystring
Guangzhou
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biosimilar development, antibody therapeutics, oncology drug development, autoimmune disease treatments, biopharmaceutical manufacturing
Industry6 codes
PRIMARYHLAAAHAA
Monoclonal Antibody (mAb) Biosimilars
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAHAG
Oncology Biosimilars
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAFAL
Other Recombinant Protein Biosimilars (non-mAb, non-hormone)
SECONDARYHLAAAJAE
Automation, Controls & Manufacturing Execution for Bioprocessing (SCADA/DCS/PLC/MES)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Biosimilars and Biopharmaceuticals
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Biosimilar Licensing & Royalty Revenue
TypeLicensing Royalties
Description

Bio-Thera develops and manufactures biosimilars while licensing commercialization rights to regional pharmaceutical partners. Partners pay upfront fees, milestone payments upon regulatory achievements, and ongoing royalties on net sales. For example, STADA deal for Gotenfia worth up to USD157.5 million plus royalties; STADA deal for BAT1806 up to EUR136 million plus double-digit royalties; BAT2506 with Intas/Accord across US, Canada, and India markets.

bio-thera.com
2Product Sales (Domestic China)
TypeOne Time License
Description

Direct commercialization of approved products in China including 格乐立® (adalimumab), 施瑞立® (tocilizumab), 普贝希® (bevacizumab), 贝塔宁® (bivalirudin), 艾沙力®/喜沙立® (ustekinumab). In April 2026, Bio-Thera transferred rights to 贝塔宁® to Lepu Pharmaceutical for RMB 450 million plus single-digit royalties on net sales for up to 10 years, indicating strategic monetization of mature products.

bio-thera.com
3Milestone Payments from Partners
TypeLicensing Royalties
Description

Receipt of milestone payments upon achievement of regulatory and development milestones from commercial partners. Recent announcements confirm receipt of milestone payments from STADA (BAT2506 and BAT1806), Gedeon Richter (BAT2206), Hikma (BAT2206), Sandoz (BAT1706), and Intas (BAT2506).

bio-thera.com
4Innovation Drug Development
TypeOne Time License
Description

Development and potential commercialization of proprietary innovative drugs including BAT4406F (CD20, NMOSD filing), BAT5906 (VEGF, nAMD filing), BAT8006 (FRα ADC, Phase III), BAT8008 (Trop2 ADC, Phase I), BAT1308 (PD-1), BAT7111 (PD-1/4-1BB bispecific), and BAT7205 (PD-L1/IL-15). Revenue from innovative drugs will come upon regulatory approvals and product sales.

bio-thera.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels9 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components1 value
Technology or R&D
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1BAT
Description

Internal development code prefix for pipeline candidates (e.g., BAT2506, BAT2206, BAT1308, BAT8008)

bio-thera.com
Core offering1 text field

Bio-Thera Solutions is a global biopharmaceutical company that develops, manufactures, and commercializes innovative antibody drugs and biosimilars for oncology, autoimmune diseases, cardiovascular diseases, and ophthalmology. The company has 8 commercialized products (adalimumab, bevacizumab, tocilizumab, bivalirudin, ustekinumab, and golimumab biosimilars) approved across China, US, EU, UK, Brazil, Switzerland, and Singapore, plus a pipeline of ADCs, bispecific antibodies, and innovative monoclonal antibodies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • BAT8008 (Trop2 ADC) in cervical cancer: cORR 29.3%, DCR 75.6%, mPFS 6.7 months, mDoR 9.0 months, mOS 17.8 months at 2.4 mg/kg dose (N=41)
+5 more records
Product overview1 text field

Bio-Thera Solutions is a global biopharmaceutical company developing novel drugs and biosimilars for oncology, autoimmune diseases, cardiovascular diseases, and ophthalmology. The company operates a platform of marketed products including 6 approved biosimilars/innovative drugs (adalimumab, bevacizumab, tocilizumab, ustekinumab, golimumab, and betrifbatide) with global reach across China, US, EU, UK, Brazil, Switzerland, and Singapore. The pipeline includes multiple ADC candidates (BAT8006/FRα, BAT8008/Trop2, BAT8010/HER2, BAT8013/CD25), bispecific antibodies (BAT7104/PD-L1-CD47, BAT7111/PD-1-4-1BB, BAT7205/PD-L1-IL-15), innovative mAbs (BAT4406F/CD20, BAT1308/PD-1, BAT4706/CTLA-4), and additional biosimilars (BAT2306/secukinumab, BAT2406/dupilumab, BAT2606/mepolizumab, BAT3306/pembrolizumab). The company has established global commercialization partnerships with STADA (EU), Accord BioPharma/Intas (US, Canada, India), Hikma (US), Gedeon Richter (EU), Dr. Reddy's (Southeast Asia), Jamjoom (MENA), Avalon (MENA), and SteinCares (Latin America).

Product and service6 records
1格乐立®/Qletli® (BAT1406 Adalimumab Biosimilar)
CategoryBiosimilar
Description

TNF-α inhibitor biosimilar referencing Humira® for treating autoimmune diseases including rheumatoid arthritis, psoriasis, ankylosing spondylitis, Crohn's disease, and uveitis. Approved in China and UK (as Qletli®).

2普贝希®/Avzivi®/Bevyx® (BAT1706 Bevacizumab Biosimilar)
CategoryBiosimilar
Description

VEGF inhibitor biosimilar referencing Avastin® for oncology indications including non-small cell lung cancer, colorectal cancer, glioblastoma, ovarian cancer, and cervical cancer. Approved in China (普贝希®), EU/US (Avzivi®), and Brazil (Bevyx®).

3施瑞立®/TOFIDENCE® (BAT1806 Tocilizumab Biosimilar)
CategoryBiosimilar
Description

IL-6R inhibitor biosimilar referencing Actemra® for rheumatoid arthritis, juvenile idiopathic arthritis, cytokine release syndrome, and COVID-19. First China-developed mAb approved by FDA. Approved in China (施瑞立®), US (TOFIDENCE®), EU, Switzerland, and UK.

4贝塔宁® (BAT2094 Bivalirudin / Citric Acid Bivatide)
CategoryInnovative Drug
Description

Innovative Category 1 chemical drug, peptide β3 integrin receptor inhibitor for acute coronary syndrome patients undergoing PCI to reduce acute occlusion, stent thrombosis, and no-reflow risks. Approved in China; product rights transferred to Lepu Pharmaceutical in April 2026.

5艾沙力®/喜沙立®/STARJEMZA®/Usymro® (BAT2206 Ustekinumab Biosimilar)
CategoryBiosimilar
Description

IL-12/IL-23 p40 subunit inhibitor biosimilar referencing Stelara® for plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. Approved in China (艾沙力®/喜沙立®), US (STARJEMZA®), EU (Usymro®), UK, Brazil, Switzerland, and Singapore.

6Gotenfia®/IMMGOLIS®/IMMGOLIS INTRI® (BAT2506 Golimumab Biosimilar)
CategoryBiosimilar
Description

First FDA-approved golimumab biosimilar referencing Simponi®/Simponi Aria®, TNF-α inhibitor for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, and juvenile idiopathic arthritis. Approved in EU (Gotenfia®) and US (IMMGOLIS®/IMMGOLIS INTRI®).

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-02-01
Description

In February 2026, Bio-Thera signed a licensing and commercialization agreement with Avalon Pharma for BAT3306 (pembrolizumab biosimilar) covering Saudi Arabia and the wider MENA region. Bio-Thera handles development, manufacturing, and supply while Avalon pursues regulatory approvals and leads commercialization. The partnership aims to expand access to immuno-oncology medicines in the MENA region.

Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-11-01
Description

In November 2025, Bio-Thera expanded partnership with Dr. Reddy's for BAT2306 (secukinumab biosimilar) in Southeast Asian markets including Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, Philippines, Thailand, and Vietnam. Dr. Reddy's has exclusive distribution and sales rights and handles registration and commercialization. Bio-Thera handles development, manufacturing, and supply.

3Jamjoom Pharma (Jamjoom Pharmaceuticals Factory Company)
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-09-01
Description

In September 2025, Bio-Thera signed a licensing and commercialization agreement with Jamjoom Pharma for BAT2306 (secukinumab biosimilar) covering Middle East and North Africa markets. Jamjoom has exclusive distribution and sales rights and handles registration and market access. Bio-Thera handles development, manufacturing, and supply.

bio-thera.com
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-06-01
Description

In June 2025, Bio-Thera partnered with SteinCares S.A. to commercialize BAT2406 (dupilumab biosimilar) for treating chronic inflammatory diseases throughout Latin America. The partnership combines Bio-Thera's biologics development expertise with SteinCares's regional registration and commercialization capabilities.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-04-01
Description

In April 2025, Organon acquired US rights to TOFIDENCE® (tocilizumab-bavi) intravenous formulation from Bio-Thera. TOFIDENCE was first approved by US FDA in May 2024. Organon handles US market promotion and sales while Bio-Thera maintains manufacturing and commercial supply. In June 2026, FDA approved expanded indications for TOFIDENCE including CAR T cell-induced CRS and pediatric COVID-19.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-02-01
Description

In February 2025, Bio-Thera signed an exclusive licensing and commercialization agreement with Intas Pharmaceuticals for BAT2506 (golimumab biosimilar) in the US market. Accord BioPharma (Intas's US subsidiary) commercializes the product in the US. In October 2025, the partnership expanded to include Canada. In March 2026, it further expanded to India. Bio-Thera handles development, manufacturing, and supply while Accord handles commercialization. Under the 2026 expansion, Intas has exclusive commercialization rights in US, Canada, and India.

Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-10-01
Description

In October 2024, Bio-Thera partnered with Gedeon Richter for BAT2206 (ustekinumab biosimilar) commercialization in EU, UK, Switzerland, Australia, and other European countries. Bio-Thera handles development, manufacturing, and supply while Gedeon Richter handles commercialization. Usymro® received EU approval in August 2025 and UK MHRA approval in February 2026.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-05-01
Description

In May 2024, Bio-Thera partnered with STADA for Gotenfia® (BAT2506, golimumab biosimilar) commercialization in EU, UK, Switzerland and other European countries. Deal worth up to USD 157.5 million plus royalties. In August 2025, partnership expanded to include BAT1806 (tocilizumab biosimilar) for EU, Switzerland, UK, other European countries, and selected MENA and CIS countries with up to EUR 136 million plus double-digit royalties. Bio-Thera handles development and manufacturing; STADA handles commercialization.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2021-08-01
Description

In August 2021, Bio-Thera signed an exclusive US commercialization agreement with Hikma for STARJEMZA® (BAT2206, ustekinumab biosimilar). Bio-Thera handles development, manufacturing, and supply while Hikma has exclusive US commercialization rights. Product launched in the US in November 2025 with milestone payments received by Bio-Thera.

Strategic tierMinorTypeOthers
Description

Adversarial relationship: Janssen Biotech filed a BPCIA patent infringement complaint in March 2026 in the US District Court for the District of Delaware against Bio-Thera Solutions and Accord BioPharma, alleging infringement of 17 patents related to their golimumab biosimilar BAT2506/IMMGOLIS. Separately, in March 2026, Accord, Intas, and Bio-Thera filed four IPR petitions challenging Janssen's Simponi patents. The dispute is ongoing.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Henlius
TypeDirect peer
Description

Shanghai-based biopharmaceutical company developing and commercializing biosimilars (adalimumab, bevacizumab, trastuzumab, rituximab) and oncology innovation drugs with global regulatory approvals. Closest China-headquartered biosimilar peer with overlapping mAb pipeline and established partnerships.

TypeDirect peer
Description

China-listed biotech developing monoclonal antibody biosimilars and innovative oncology biologics including PD-1 inhibitors and bispecifics. Directly comparable in combining a biosimilar base with a proprietary innovation pipeline targeting similar indications.

TypeDirect peer
Description

Shanghai-listed Chinese biopharma with both biosimilar and innovative antibody programs across oncology and autoimmune disease. Comparable in mAb development depth, Chinese listing, and global regulatory strategy.

TypeDirect peer
Description

South Korea-based biosimilar leader with FDA/EMA-approved infliximab (Inflectra), rituximab (Truxima), trastuzumab (Herzuma), and other mAb biosimilars. Closest non-Chinese direct peer in mAb biosimilars with global commercial partnerships.

TypeDirect peer
Description

Joint venture between Samsung Biologics and Biogen developing and commercializing biosimilars including adalimumab, etanercept, infliximab, ranibizumab, trastuzumab. Highly comparable in mAb biosimilar pipeline and global commercialization partnerships.

TypeDirect peer
Description

Iceland-based pure-play biosimilar developer focused on mAb biosimilars (adalimumab, ustekinumab, aflibercept) with FDA/EMA approvals and global partner network. Comparable in narrow portfolio of mAb biosimilars plus manufacturing scale at Reykjavik hub.

TypeDirect peer
Description

India-based subsidiary of Biocon Limited developing monoclonal antibody biosimilars (trastuzumab, bevacizumab, adalimumab, etanercept) with FDA/EMA approvals and global commercial partnerships. Comparable emerging-market biosimilar developer with similar international partner strategy.

8Shanghai Pharmaceuticals Holding
TypeBroad incumbent
Description

Large state-linked Chinese pharmaceutical group with broad generics, APIs, and biopharmaceutical operations including biosimilars. Comparable as a China-headquartered broader pharmaceutical player whose biologicals segment overlaps with Bio-Thera.

TypeBroad incumbent
Description

Global oncology-focused biotech with PD-1 inhibitor (tislelizumab) and broad hematology portfolio approved in U.S. and China. Comparable as a China-headquartered biopharma with innovative antibody drugs and global commercial footprint, though focused on innovation rather than biosimilars.

TypeOthers
Description

China-based biologics contract development and manufacturing organization with large-scale bioreactor capacity and biosimilar/innovator co-development. Comparable as a China-headquartered biologics manufacturer; a potential CDMO partner or competitor for Bio-Thera's manufacturing footprint.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries8 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Bio-Thera Solutions

Biosimilars and Biopharmaceuticalsbio-thera.com

Bio-Thera Solutions is a Guangzhou-based, publicly listed Chinese biopharmaceutical company developing biosimilars and innovative antibody drugs (including ADCs and bispecifics) for cancer, autoimmune, cardiovascular, and ophthalmic diseases, commercializing via global regional partners.

What Bio-Thera Solutions does

Bio-Thera Solutions (百奥泰生物制药股份有限公司) is a Guangzhou-headquartered, publicly listed (Shanghai STAR Market, ticker 688177) commercial-stage biopharmaceutical company founded in 2003 that develops both biosimilars and innovative antibody drugs for oncology, autoimmune disease, cardiovascular disease, and ophthalmology. Its six proprietary technology platforms span antibody discovery (IDEAL engine, libraries of thousands of unique human antibody clones), AI-driven sequence-structure-function optimization, ADCC enhancement and Fc engineering, bispecific/multispecific dual-payload ADC construction with proprietary cleavable linkers, proprietary cell culture medium development, and full-chain quality research aligned with NMPA, FDA, and EMA standards. The company has 8 commercialized products: 格乐立®/Qletli® (adalimumab), 普贝希®/Avzivi®/Bevyx® (bevacizumab), 施瑞立®/TOFIDENCE® (tocilizumab), 贝塔宁® (bivalirudin, since transferred to Lepu in April 2026), 艾沙力®/喜沙立®/STARJEMZA®/Usymro® (ustekinumab), Gotenfia®/IMMGOLIS™ (golimumab), plus two BLAs under review (BAT4406F for NMOSD and BAT5906 for nAMD). The pipeline also includes multiple ADC candidates (BAT8006 FRα, BAT8008 Trop2, BAT8010 HER2, BAT8013 CD25), bispecific antibodies (BAT7111 PD-1/4-1BB, BAT7205 PD-L1/IL-15, BAT7104 PD-L1/CD47), and additional biosimilars (secukinumab, dupilumab, mepolizumab, pembrolizumab).

The business model is hybrid: Bio-Thera retains development, manufacturing, and supply of all products globally (66,500L current bioreactor capacity with 72,000L expansion planned at Yonghe, 91,744 m² facility), commercializes approved products directly in mainland China, and licenses regional commercialization rights to established pharmaceutical partners across the US (Accord BioPharma/Intas, Organon, Hikma), EU/UK/Switzerland (STADA, Gedeon Richter), MENA (Avalon, Jamjoom), Southeast Asia (Dr. Reddy's), Latin America (SteinCares), Canada (Accord), and India (Intas). Revenue mechanics include upfront fees, regulatory and development milestone payments, royalties on partner net sales (BAT2206 reaches 71+ countries), direct product sales in China, and one-time license transactions for mature assets (the CNY 450M Lepu deal being the most recent example). GMP certifications have been granted by NMPA, FDA, EMA, and ANVISA, supporting multi-region market access.

Bio-Thera Solutions firmographics

Firmographics
Name
Bio-Thera Solutions
Legal name
百奥泰生物制药股份有限公司
Website
https://bio-thera.com
Company type
Public
Founded year
2003
Operating status
Operating
Headcount range
11–50 employees
Short description
Bio-Thera Solutions is a Guangzhou-based, publicly listed Chinese biopharmaceutical company developing biosimilars and innovative antibody drugs (including ADCs and bispecifics) for cancer, autoimmune, cardiovascular, and ophthalmic diseases, commercializing via global regional partners.
Ownership category
akta.pro rank

Bio-Thera Solutions industry classification

Industry
Product category
Biosimilars and Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAHAA
Monoclonal Antibody (mAb) Biosimilars
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAHAG
Oncology Biosimilars
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAFAL
Other Recombinant Protein Biosimilars (non-mAb, non-hormone)
SECONDARYHLAAAJAE
Automation, Controls & Manufacturing Execution for Bioprocessing (SCADA/DCS/PLC/MES)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)

Keywords

  • Biosimilar development
  • Antibody therapeutics
  • Oncology drug development
  • Autoimmune disease treatments
  • Biopharmaceutical manufacturing

Where Bio-Thera Solutions is headquartered

Location

Headquarters

HQ city
Guangzhou
HQ country
China
HQ region
Asia

Offices3 records

Markets served

Bio-Thera Solutions business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D

Revenue model

  1. Biosimilar Licensing & Royalty Revenue: Bio-Thera develops and manufactures biosimilars while licensing commercialization rights to regional pharmaceutical partners. Partners pay upfront fees, milestone payments upon regulatory achievements, and ongoing royalties on net sales. For example, STADA deal for Gotenfia worth up to USD157.5 million plus royalties; STADA deal for BAT1806 up to EUR136 million plus double-digit royalties; BAT2506 with Intas/Accord across US, Canada, and India markets.
  2. Product Sales (Domestic China): Direct commercialization of approved products in China including 格乐立® (adalimumab), 施瑞立® (tocilizumab), 普贝希® (bevacizumab), 贝塔宁® (bivalirudin), 艾沙力®/喜沙立® (ustekinumab). In April 2026, Bio-Thera transferred rights to 贝塔宁® to Lepu Pharmaceutical for RMB 450 million plus single-digit royalties on net sales for up to 10 years, indicating strategic monetization of mature products.
  3. Milestone Payments from Partners: Receipt of milestone payments upon achievement of regulatory and development milestones from commercial partners. Recent announcements confirm receipt of milestone payments from STADA (BAT2506 and BAT1806), Gedeon Richter (BAT2206), Hikma (BAT2206), Sandoz (BAT1706), and Intas (BAT2506).
  4. Innovation Drug Development: Development and potential commercialization of proprietary innovative drugs including BAT4406F (CD20, NMOSD filing), BAT5906 (VEGF, nAMD filing), BAT8006 (FRα ADC, Phase III), BAT8008 (Trop2 ADC, Phase I), BAT1308 (PD-1), BAT7111 (PD-1/4-1BB bispecific), and BAT7205 (PD-L1/IL-15). Revenue from innovative drugs will come upon regulatory approvals and product sales.

Go-to-market motion2 records

Distribution channels9 records

Marketing channels6 records

Bio-Thera Solutions product offering

Product offering

Core offering

Bio-Thera Solutions is a global biopharmaceutical company that develops, manufactures, and commercializes innovative antibody drugs and biosimilars for oncology, autoimmune diseases, cardiovascular diseases, and ophthalmology. The company has 8 commercialized products (adalimumab, bevacizumab, tocilizumab, bivalirudin, ustekinumab, and golimumab biosimilars) approved across China, US, EU, UK, Brazil, Switzerland, and Singapore, plus a pipeline of ADCs, bispecific antibodies, and innovative monoclonal antibodies.

Product overview

Bio-Thera Solutions is a global biopharmaceutical company developing novel drugs and biosimilars for oncology, autoimmune diseases, cardiovascular diseases, and ophthalmology. The company operates a platform of marketed products including 6 approved biosimilars/innovative drugs (adalimumab, bevacizumab, tocilizumab, ustekinumab, golimumab, and betrifbatide) with global reach across China, US, EU, UK, Brazil, Switzerland, and Singapore. The pipeline includes multiple ADC candidates (BAT8006/FRα, BAT8008/Trop2, BAT8010/HER2, BAT8013/CD25), bispecific antibodies (BAT7104/PD-L1-CD47, BAT7111/PD-1-4-1BB, BAT7205/PD-L1-IL-15), innovative mAbs (BAT4406F/CD20, BAT1308/PD-1, BAT4706/CTLA-4), and additional biosimilars (BAT2306/secukinumab, BAT2406/dupilumab, BAT2606/mepolizumab, BAT3306/pembrolizumab). The company has established global commercialization partnerships with STADA (EU), Accord BioPharma/Intas (US, Canada, India), Hikma (US), Gedeon Richter (EU), Dr. Reddy's (Southeast Asia), Jamjoom (MENA), Avalon (MENA), and SteinCares (Latin America).

Differentiator

Problem solved

Functional benefit

Brands

  • BAT: Internal development code prefix for pipeline candidates (e.g., BAT2506, BAT2206, BAT1308, BAT8008)

Products and services

  • 格乐立®/Qletli® (BAT1406 Adalimumab Biosimilar) TNF-α inhibitor biosimilar referencing Humira® for treating autoimmune diseases including rheumatoid arthritis, psoriasis, ankylosing spondylitis, Crohn's disease, and uveitis. Approved in China and UK (as Qletli®).
  • 普贝希®/Avzivi®/Bevyx® (BAT1706 Bevacizumab Biosimilar) VEGF inhibitor biosimilar referencing Avastin® for oncology indications including non-small cell lung cancer, colorectal cancer, glioblastoma, ovarian cancer, and cervical cancer. Approved in China (普贝希®), EU/US (Avzivi®), and Brazil (Bevyx®).
  • 施瑞立®/TOFIDENCE® (BAT1806 Tocilizumab Biosimilar) IL-6R inhibitor biosimilar referencing Actemra® for rheumatoid arthritis, juvenile idiopathic arthritis, cytokine release syndrome, and COVID-19. First China-developed mAb approved by FDA. Approved in China (施瑞立®), US (TOFIDENCE®), EU, Switzerland, and UK.
  • 贝塔宁® (BAT2094 Bivalirudin / Citric Acid Bivatide) Innovative Category 1 chemical drug, peptide β3 integrin receptor inhibitor for acute coronary syndrome patients undergoing PCI to reduce acute occlusion, stent thrombosis, and no-reflow risks. Approved in China; product rights transferred to Lepu Pharmaceutical in April 2026.
  • 艾沙力®/喜沙立®/STARJEMZA®/Usymro® (BAT2206 Ustekinumab Biosimilar) IL-12/IL-23 p40 subunit inhibitor biosimilar referencing Stelara® for plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. Approved in China (艾沙力®/喜沙立®), US (STARJEMZA®), EU (Usymro®), UK, Brazil, Switzerland, and Singapore.
  • Gotenfia®/IMMGOLIS®/IMMGOLIS INTRI® (BAT2506 Golimumab Biosimilar) First FDA-approved golimumab biosimilar referencing Simponi®/Simponi Aria®, TNF-α inhibitor for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, and juvenile idiopathic arthritis. Approved in EU (Gotenfia®) and US (IMMGOLIS®/IMMGOLIS INTRI®).

Quantifiable outcome

  • BAT8008 (Trop2 ADC) in cervical cancer: cORR 29.3%, DCR 75.6%, mPFS 6.7 months, mDoR 9.0 months, mOS 17.8 months at 2.4 mg/kg dose (N=41)
  • +5 more outcomes

Companies that use Bio-Thera Solutions

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles2 records

Bio-Thera Solutions technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Bio-Thera Solutions partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered minor and core.

  • Avalon PharmaminorChannel Partner/ Reseller/ Distributor · 1 February 2026In February 2026, Bio-Thera signed a licensing and commercialization agreement with Avalon Pharma for BAT3306 (pembrolizumab biosimilar) covering Saudi Arabia and the wider MENA region. Bio-Thera handles development, manufacturing, and supply while Avalon pursues regulatory approvals and leads commercialization. The partnership aims to expand access to immuno-oncology medicines in the MENA region.
  • Dr. Reddy's Laboratories Ltd.minorChannel Partner/ Reseller/ Distributor · 1 November 2025In November 2025, Bio-Thera expanded partnership with Dr. Reddy's for BAT2306 (secukinumab biosimilar) in Southeast Asian markets including Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, Philippines, Thailand, and Vietnam. Dr. Reddy's has exclusive distribution and sales rights and handles registration and commercialization. Bio-Thera handles development, manufacturing, and supply.
  • Jamjoom Pharma (Jamjoom Pharmaceuticals Factory Company)minorChannel Partner/ Reseller/ Distributor · 1 September 2025In September 2025, Bio-Thera signed a licensing and commercialization agreement with Jamjoom Pharma for BAT2306 (secukinumab biosimilar) covering Middle East and North Africa markets. Jamjoom has exclusive distribution and sales rights and handles registration and market access. Bio-Thera handles development, manufacturing, and supply.
  • SteinCares S.A.minorChannel Partner/ Reseller/ Distributor · 1 June 2025In June 2025, Bio-Thera partnered with SteinCares S.A. to commercialize BAT2406 (dupilumab biosimilar) for treating chronic inflammatory diseases throughout Latin America. The partnership combines Bio-Thera's biologics development expertise with SteinCares's regional registration and commercialization capabilities.
  • Organon LLCcoreChannel Partner/ Reseller/ Distributor · 1 April 2025In April 2025, Organon acquired US rights to TOFIDENCE® (tocilizumab-bavi) intravenous formulation from Bio-Thera. TOFIDENCE was first approved by US FDA in May 2024. Organon handles US market promotion and sales while Bio-Thera maintains manufacturing and commercial supply. In June 2026, FDA approved expanded indications for TOFIDENCE including CAR T cell-induced CRS and pediatric COVID-19.
  • Accord BioPharma (Intas Pharmaceuticals US subsidiary)coreChannel Partner/ Reseller/ Distributor · 1 February 2025In February 2025, Bio-Thera signed an exclusive licensing and commercialization agreement with Intas Pharmaceuticals for BAT2506 (golimumab biosimilar) in the US market. Accord BioPharma (Intas's US subsidiary) commercializes the product in the US. In October 2025, the partnership expanded to include Canada. In March 2026, it further expanded to India. Bio-Thera handles development, manufacturing, and supply while Accord handles commercialization. Under the 2026 expansion, Intas has exclusive commercialization rights in US, Canada, and India.
  • Gedeon Richter Plc. (吉瑞医药)minorChannel Partner/ Reseller/ Distributor · 1 October 2024In October 2024, Bio-Thera partnered with Gedeon Richter for BAT2206 (ustekinumab biosimilar) commercialization in EU, UK, Switzerland, Australia, and other European countries. Bio-Thera handles development, manufacturing, and supply while Gedeon Richter handles commercialization. Usymro® received EU approval in August 2025 and UK MHRA approval in February 2026.
  • STADA Arzneimittel AGcoreChannel Partner/ Reseller/ Distributor · 1 May 2024In May 2024, Bio-Thera partnered with STADA for Gotenfia® (BAT2506, golimumab biosimilar) commercialization in EU, UK, Switzerland and other European countries. Deal worth up to USD 157.5 million plus royalties. In August 2025, partnership expanded to include BAT1806 (tocilizumab biosimilar) for EU, Switzerland, UK, other European countries, and selected MENA and CIS countries with up to EUR 136 million plus double-digit royalties. Bio-Thera handles development and manufacturing; STADA handles commercialization.
  • Hikma Pharmaceuticals USA Inc.coreChannel Partner/ Reseller/ Distributor · 1 August 2021In August 2021, Bio-Thera signed an exclusive US commercialization agreement with Hikma for STARJEMZA® (BAT2206, ustekinumab biosimilar). Bio-Thera handles development, manufacturing, and supply while Hikma has exclusive US commercialization rights. Product launched in the US in November 2025 with milestone payments received by Bio-Thera.
  • Janssen Biotech / Janssen Sciences Ireland UCminorOthersAdversarial relationship: Janssen Biotech filed a BPCIA patent infringement complaint in March 2026 in the US District Court for the District of Delaware against Bio-Thera Solutions and Accord BioPharma, alleging infringement of 17 patents related to their golimumab biosimilar BAT2506/IMMGOLIS. Separately, in March 2026, Accord, Intas, and Bio-Thera filed four IPR petitions challenging Janssen's Simponi patents. The dispute is ongoing.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Bio-Thera Solutions competitors and assessment

Company assessment

Direct peers

  • Henlius: Shanghai-based biopharmaceutical company developing and commercializing biosimilars (adalimumab, bevacizumab, trastuzumab, rituximab) and oncology innovation drugs with global regulatory approvals. Closest China-headquartered biosimilar peer with overlapping mAb pipeline and established partnerships.
  • Innovent Biologics: China-listed biotech developing monoclonal antibody biosimilars and innovative oncology biologics including PD-1 inhibitors and bispecifics. Directly comparable in combining a biosimilar base with a proprietary innovation pipeline targeting similar indications.
  • Shanghai Junshi Biosciences: Shanghai-listed Chinese biopharma with both biosimilar and innovative antibody programs across oncology and autoimmune disease. Comparable in mAb development depth, Chinese listing, and global regulatory strategy.
  • Celltrion: South Korea-based biosimilar leader with FDA/EMA-approved infliximab (Inflectra), rituximab (Truxima), trastuzumab (Herzuma), and other mAb biosimilars. Closest non-Chinese direct peer in mAb biosimilars with global commercial partnerships.
  • Samsung Bioepis: Joint venture between Samsung Biologics and Biogen developing and commercializing biosimilars including adalimumab, etanercept, infliximab, ranibizumab, trastuzumab. Highly comparable in mAb biosimilar pipeline and global commercialization partnerships.
  • Alvotech: Iceland-based pure-play biosimilar developer focused on mAb biosimilars (adalimumab, ustekinumab, aflibercept) with FDA/EMA approvals and global partner network. Comparable in narrow portfolio of mAb biosimilars plus manufacturing scale at Reykjavik hub.
  • Biocon Biologics: India-based subsidiary of Biocon Limited developing monoclonal antibody biosimilars (trastuzumab, bevacizumab, adalimumab, etanercept) with FDA/EMA approvals and global commercial partnerships. Comparable emerging-market biosimilar developer with similar international partner strategy.

Broad incumbents

  • Shanghai Pharmaceuticals Holding: Large state-linked Chinese pharmaceutical group with broad generics, APIs, and biopharmaceutical operations including biosimilars. Comparable as a China-headquartered broader pharmaceutical player whose biologicals segment overlaps with Bio-Thera.
  • BeiGene: Global oncology-focused biotech with PD-1 inhibitor (tislelizumab) and broad hematology portfolio approved in U.S. and China. Comparable as a China-headquartered biopharma with innovative antibody drugs and global commercial footprint, though focused on innovation rather than biosimilars.

Others

  • WuXi Biologics: China-based biologics contract development and manufacturing organization with large-scale bioreactor capacity and biosimilar/innovator co-development. Comparable as a China-headquartered biologics manufacturer; a potential CDMO partner or competitor for Bio-Thera's manufacturing footprint.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Bio-Thera Solutions social profiles

Digital presence

Bio-Thera Solutions compliance and trust

Trust signal

Compliance4 records

Bio-Thera Solutions financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Bio-Thera Solutions leadership team

Management profile

Number of profiles

Profiles2 records

Bio-Thera Solutions subsidiaries and ownership

Company hierarchy

Subsidiaries8 records

Bio-Thera Solutions funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Bio-Thera Solutions M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bio-Thera Solutions

What does Bio-Thera Solutions do?

Bio-Thera Solutions is a global biopharmaceutical company that develops, manufactures, and commercializes innovative antibody drugs and biosimilars for oncology, autoimmune diseases, cardiovascular diseases, and ophthalmology. The company has 8 commercialized products (adalimumab, bevacizumab, tocilizumab, bivalirudin, ustekinumab, and golimumab biosimilars) approved across China, US, EU, UK, Brazil, Switzerland, and Singapore, plus a pipeline of ADCs, bispecific antibodies, and innovative monoclonal antibodies.

Is Bio-Thera Solutions a public or private company?

Bio-Thera Solutions is a public company. It is classified as public and is currently operating.

When was Bio-Thera Solutions founded?

Bio-Thera Solutions was founded in 2003. It employs 11 to 50 people.

Where is Bio-Thera Solutions based?

Bio-Thera Solutions is headquartered in Guangzhou, China, in the Asia region.

How does Bio-Thera Solutions make money?

Four revenue lines are on record. Biosimilar Licensing & Royalty Revenue is the primary driver. The others are product Sales (Domestic China), milestone Payments from Partners and innovation Drug Development.

Who are Bio-Thera Solutions's main competitors?

Direct peers on record are Henlius, Innovent Biologics, Shanghai Junshi Biosciences, Celltrion, Samsung Bioepis, Alvotech and Biocon Biologics. Broad incumbents are Shanghai Pharmaceuticals Holding and BeiGene. WuXi Biologics is listed as an others.

Does Bio-Thera Solutions have an API?

No public API is recorded for Bio-Thera Solutions.

What industry is Bio-Thera Solutions in?

Bio-Thera Solutions's product category is Biosimilars and Biopharmaceuticals. Its primary akta.pro industry code is HLAAAHAA, Monoclonal Antibody (mAb) Biosimilars, with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Pharmaceutical TechnologyBio-Thera receives NMPA authorisation for BAT2506 in ChinaChina's NMPA granted marketing authorisation for Bio-Thera Solutions' BAT2506 to treat ankylosing spondylitis and rheumatoid arthritis, to be marketed as Ashuli. It is the first Simponi (golimumab) biosimilar approved in China, offering a lower-cost option amid domestic demand for affordable biologics.MoomooBiocytogen (02315) to enter a new phase of 'scaled profitability' in the first three quarters of 2026Bio-Thera Solutions reported Q3 2026 revenue of RMB 1.403 billion, up 49.09% year over year, with net profit of RMB 312 million, up 173.77%. Operating cash flow reached RMB 160 million, up 170.13%, and the company has transitioned to scale-driven profitability.MoomooHong Kong Stock Market Watch: Bio-Thera Solutions-B (02315) surges over 8% in early trading; Q3 results to be released tomorrow, with institutions bullish on further performance improvementBio-Thera Solutions-B rose over 8% in early trading, trading at HK$42.82. The company will hold a board meeting on October 29 to approve Q3 results, with interim revenue up 51.6% year-on-year. CICC expects further profitability improvement from cost dilution and clinical progress.MoomooZhitong Statistics on Significant Changes in Stock Connect Holdings | October 26On October 23, 2026, Jingwei Tiandi, E Fund Asia High Dividend, and Tianyue Advanced saw the largest increases in Stock Connect shareholding ratios, rising by 13.23%, 2.95%, and 1.82% respectively. Chifeng Gold, Lanqi Technology, and Bio-Thera Solutions-B recorded the largest decreases, falling by 20.26%, 1.31%, and 1.22%.医药魔方-致力于数据赋能医药创新,助力高效决策与数智化转型Bio-Thera Secures First Global Secukinumab Biosimilar ApprovalBio-Thera Solutions received NMPA approval for BAT2306, a secukinumab biosimilar, the world's first approved biosimilar to Novartis' Cosentyx. Secukinumab's 2025 brand sales were USD 6.668 billion, opening a large immunology franchise to biosimilar competition. Competitors CSPC and Celltrion have filed but not yet approved applications.Clinical Trials ArenaDosing commences in Bio-Thera’s Phase I solid tumour study of BAT8013Bio-Thera Solutions initiated dosing in a Phase I trial of BAT8013, an anti-CD25 antibody drug conjugate, in patients with advanced solid tumours. The dose-escalation study aims to assess tolerability, safety, and identify the recommended dose for Phase II trials. The company is advancing over 20 clinical candidates, including other ADCs and immuno-oncology assets.BioSpaceBio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT8013, an Antibody Drug Conjugate Targeting CD25 for the Treatment of Advanced Solid TumorsBio-Thera Solutions announced first patient dosing in a Phase 1 study of BAT8013, an antibody-drug conjugate targeting CD25 for advanced solid tumors. The study aims to assess safety, tolerability, and determine the recommended Phase 2 dose. The company is also developing additional ADCs and oncology assets in early-stage trials.PR NewswireBio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT8013, an Antibody Drug Conjugate Targeting CD25 for the Treatment of Advanced Solid TumorsBio-Thera Solutions announced dosing has begun in a Phase 1 clinical study of BAT8013, an antibody drug conjugate targeting CD25 for advanced solid tumors. The study aims to assess safety, tolerability, and determine the recommended Phase 2 dose. The company is also developing additional ADCs and innovative oncology assets.Phirda百利天恒,正在学会成为一家 MNCBaili Tianheng's iza-bren ADC received approval for recurrent nasopharyngeal cancer, becoming the first global dual-antibody ADC. The company also independently launched the global Phase III trial for its DLL3 ADC, BL-M14D1, in small-cell lung cancer. The firm targets becoming an entry-level MNC by 2030 and a full MNC by 2035.YicaiglobalChina's Bio-Thera Gets US Nod for Golimumab BiosimilarBio-Thera Solutions announced that its golimumab biosimilar BAT2506 received FDA approval for treating rheumatoid arthritis and ulcerative colitis. The drug, available in subcutaneous and intravenous formulations, is a biosimilar to Simponi and Gobivaz, and has been approved in 118 countries and regions.